Molecular approaches to therapy for Duchenne and limb-girdle muscular dystrophy

Current Opinion in Molecular Therapeutics

Volumn 3, Issue 4, 2001, Pages 350-356

  Stedman, H H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Dystrophin; Gene transfer; Integrin 7; Mdx mouse; Muscular dystrophy

Indexed keywords

ACTIN; ADENINE; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CALCIUM; CALPAIN; COLLAGEN TYPE 4; COMPLEMENTARY DNA; CYTIDINE; CYTOSKELETON PROTEIN; DNA; DYSTROGLYCAN; DYSTROPHIN; GENE PRODUCT; GENTAMICIN; IMMUNOSUPPRESSIVE AGENT; INTEGRIN; LAMININ; MATRIX PROTEIN; MEMBRANE PROTEIN; OLIGORIBONUCLEOTIDE; PYRIMIDINE; SARCOGLYCAN; SCLEROPROTEIN; SPECTRIN; TACROLIMUS; UNINDEXED DRUG; URACIL; UTROPHIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSFER; CLINICAL RESEARCH; CONTROLLED STUDY; CYTOLOGY; DNA VECTOR; DRUG ACTIVITY; DUCHENNE MUSCULAR DYSTROPHY; GENE TECHNOLOGY; GENE TRANSFER; GENETIC HETEROGENEITY; HUMAN; HUMAN EXPERIMENT; INHERITANCE; LIMB GIRDLE MUSCULAR DYSTROPHY; MOLECULAR GENETICS; MOUSE; MUSCLE ATROPHY; MUSCLE WEAKNESS; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; REVIEW; TREATMENT PLANNING;

ANIMALS; ANTIGENS, CD; DYSTROPHIN; GENE THERAPY; GENE TRANSFER, HORIZONTAL; GENETIC VECTORS; HUMANS; INTEGRIN ALPHA CHAINS; MICE; MUSCULAR DYSTROPHIES;

EID: 0034879391     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Dystrophin and its isoforms
2. Beyond dystrophin: Current progress in the muscular dystrophies
3. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene
4. Dystrophin: The protein product of the Duchenne muscular dystrophy locus
5. Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy
6. Mutations in the dystrophin-associated protein γ-sarcoglycan in chromosome 13 muscular dystrophy
7. Assembly of the sarcoglycan complex. Insights for muscular dystrophy
8. Dystrophin protects the sarcolemma from stresses developed during muscle contraction
9. The physiological evaluation of gene therapies of dystrophin-deficient muscles
10. Functional rescue of the sarcoglycan complex in the BIO 14.6 hamster using δ-sarcoglycan gene transfer
11. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector
12. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin
13. Mutations in the laminin α 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy
14. Type VI collagen mutations in Bethlem myopathy, an autosomal dominant myopathy with contractures
15. Expression profiling in the muscular dystrophies: Identification of novel aspects of molecular pathophysiology
16. Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: Evidence of apoptosis in dystrophin-deficient muscle
17. Sarcoglycans in muscular dystrophy
18. Disruption of the β-sarcoglycan gene reveals pathogenetic complexity of limbgirdle muscular dystrophy type 2E
19. Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex
20. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity
21. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy
22. Overexpression of γ-sarcoglycan induces severe muscular dystrophy: Implications for the regulation of sarcoglycan assembly
23. Expression of full-length utrophin prevents muscular dystrophy in mdx mice
24. A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy
25. Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene
26. Absence of integrin α7 causes a novel form of muscular dystrophy
27. Mutations in the integrin α7 gene cause congenital myopathy
28. Organization of the myotendinous junction is dependent on the presence of α7β1 integrin
29. Enhanced expression of the α7β1 integrin reduces muscular dystrophy and restores viability in dystrophic mice
30. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A
31. Loss of calpain 3 proteolytic activity leads to muscular dystrophy and to apoptosis-associated IκBα/nuclear factor κB pathway perturbation in mice
32. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IκBα/NF-κB pathway in limb-girdle muscular dystrophy type 2A
33. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice
34. Sequence specificity of aminoglycoside-induced stop condon readthrough: Potential implications for treatment of Duchenne muscular dystrophy
35. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations
36. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse
37. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides
38. Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides
39. In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide
40. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of mormal myoblasts
41. Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation
42. Myoblast transfer in the treatment of Duchenne's muscular dystrophy
43. Myoblast implantation in Duchenne muscular dystrophy: The San Francisco study
44. Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: Implications for cell and gene therapy
45. Telomerase allows the immortalization of T antigen-positive DMD myoblasts: A new source of cells for gene transfer application
46. Myoblast transplantation in whole muscle of non-human primates
47. Extracorporeal circulation as a new experimental pathway for myoblast implantation in mdx mice
48. Muscle regeneration by bone marrow-derived myogenic progenitors
49. Dystrophin expression in the mdx mouse restored by stem cell transplantation
50. Failure to correct murine muscular dystrophy
51. Myogenic stem cell function is impaired in mice lacking the forkhead/winged helix protein MNF
52. Pax7 is required for the specification of myogenic satellite cells
53. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
54. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors
55. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs
56. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice
57. Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene
58. Functional protection of dystrophic mouse (mdx) muscles after adenovirus-mediated transfer of a dystrophin minigene
59. Impairment of force generation after adenovirus-mediated gene transfer to muscle is alleviated by adenoviral gene inactivation and host CD8+ T-cell deficiency
60. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase
61. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells
62. In vivo expression of full length human dystrophin from adenoviral vectors deleted of all viral genes
63. An Improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus
64. Herpes simplex virus vector-mediated dystrophin gene transfer and expression in mdx mouse skeletal muscle
65. Expression of vhs and VP16 during HSV-1 helper virus-free amplicon packaging enhances titers
66. Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: α-, β-, γ-, or δ-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors
67. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
68. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adenoassociated virus vector
69. Recombinant adeno-associated virus for muscle directed gene therapy
70. rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy
71. Early adenovirus-mediated gene transfer effectively prevents muscular dystrophy in α-sarcoglycandeficient mice
72. Rescue of skeletal muscles of γ-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer
73. Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice
74. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice
75. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and non-human primate muscle
76. Role of vector in activation of T-cell subsets in immune responses against the secreted transgene product factor IX
77. Contractile properties of bundles of fiber segments from skeletal muscles
78. Length-tension relationship of mammalian diaphragm muscles
79. MS-325 EPIX
80. Contrast agent-enhanced magnetic resonance imaging of skeletal muscle damage in animal models of muscular dystrophy
81. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein
82. Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility
83. The molecular basis for Duchenne versus Becker muscular dystrophy: Correlation of severity with type of deletion
84. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain
85. Role for α-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies
86. Adeno-associated virus vector carrying human minidystrophin genes effectively amellorates muscular dystrophy in mdx mouse model
87. Muscle creatine kinase sequence elements regulating skeletal and cardiac muscle expression in transgenic mice
88. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies